Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?

Group 1 - Beam Therapeutics Inc. (BEAM) shares have increased by 22.2% in the past four weeks, closing at $28.57, with a mean price target of$47.79 indicating a potential upside of 67.3% [1] - The average of 14 short-term price targets ranges from a low of $23 to a high of$80, with a standard deviation of $20.04, suggesting variability in analyst estimates [2] - Analysts show strong agreement on BEAM's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][9] Group 2 - The Zacks Consensus Estimate for BEAM's current year earnings has increased by 4.3% over the past month, with two estimates rising and no negative revisions [10] - BEAM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [11] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide a directional guide for price movement [12]